Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $34.7 million.

  • Sutro Biopharma's Accumulated Expenses rose 790.73% to $34.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year increase of 790.73%. This contributed to the annual value of $31.2 million for FY2024, which is 1877.42% down from last year.
  • As of Q3 2025, Sutro Biopharma's Accumulated Expenses stood at $34.7 million, which was up 790.73% from $38.2 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Accumulated Expenses registered a high of $38.5 million during Q4 2023, and its lowest value of $4.5 million during Q1 2021.
  • In the last 5 years, Sutro Biopharma's Accumulated Expenses had a median value of $19.4 million in 2023 and averaged $21.2 million.
  • Within the past 5 years, the most significant YoY rise in Sutro Biopharma's Accumulated Expenses was 20457.52% (2024), while the steepest drop was 1877.42% (2024).
  • Sutro Biopharma's Accumulated Expenses (Quarter) stood at $11.4 million in 2021, then increased by 29.32% to $14.8 million in 2022, then soared by 160.59% to $38.5 million in 2023, then decreased by 18.77% to $31.2 million in 2024, then grew by 10.96% to $34.7 million in 2025.
  • Its Accumulated Expenses stands at $34.7 million for Q3 2025, versus $38.2 million for Q2 2025 and $36.6 million for Q1 2025.